Mereo Biopharma Group Plc (MREO) Stock Price & Analysis
Mereo Biopharma Group Plc (MREO) rose 0.23% to USD 0.31 as of June 10, 2026 at 06:27 UTC, according to Nexqual real-time market data.
MREO last closed at USD 0.31; the session ranged USD 0.28–0.31 on volume of 1,409,367 shares. Market capitalization is $48.80M, with a 52-week range of USD 0.2–3.05 (NCM). Source: Nexqual, June 10, 2026 at 06:27 UTC.
Key Statistics (as of June 10, 2026 at 06:27 UTC)
| Price | USD 0.31 |
|---|---|
| Change | ▲ 0.23% (up) |
| Previous Close | USD 0.31 |
| Open | USD 0.29 |
| Day Range | USD 0.28 – 0.31 |
| 52-Week Range | USD 0.2 – 3.05 |
| Volume | 1,409,367 shares |
| Market Cap | $48.80M |
| Exchange | NCM |
Technical Analysis (MREO)
Nexqual's technical model rates MREO "BUY" based on 4 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 06:27 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 49.26 (neutral) |
| vs SMA50 | Above (USD 0.3) |
| MACD | 0.01 (positive) |
Analyst Ratings (MREO)
Wall Street analysts rate MREO "None" based on 6 analysts, with a mean price target of USD 1.73 (range USD 0.5–2.97), per Nexqual as of June 10, 2026 at 06:27 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 6 |
| Mean Target | USD 1.73 |
| High Target | USD 2.97 |
| Low Target | USD 0.5 |
| Buy / Hold / Sell | 5 / 3 / 0 |
Earnings (MREO)
| Next Earnings Date | 2026-08-11 |
|---|---|
| EPS Estimate | USD -0.01 |
| Revenue Estimate | $863,830 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.01 vs est 0 ▼ miss |
| 2025-12-31 | USD -0.01 vs est -0.01 ▼ miss |
| 2025-09-30 | USD -0.01 vs est -0 ▼ miss |
| 2025-06-30 | USD -0.01 vs est -0.01 ▼ miss |
Source: Nexqual, June 10, 2026 at 06:27 UTC.
Financials & Fundamentals (MREO)
| Total Revenue | $500,000 |
|---|---|
| Gross Margin | +73.40% |
| Operating Margin | -7242.20% |
| Profit Margin | +0.00% |
| ROE | -75.87% |
| Current Ratio | 6.48 |
| Total Cash | $36.22M |
| Total Debt | $0 |
Source: Nexqual, June 10, 2026 at 06:27 UTC.
Financial Health Score (MREO)
Nexqual rates Mereo Biopharma Group Plc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 06:27 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $36M cash, no debt |
| Cash Flow | Mixed — No data |
| Efficiency | Critical — ROE -76%, ROA -41.6% |
Ownership (MREO)
| Insider Ownership | +0.96% |
|---|---|
| Institutional Ownership | +47.91% |
| Shares Outstanding | 159.62M |
| Float | 114.47M |
| Short % of Float | +6.29% |
Source: Nexqual, June 10, 2026 at 06:27 UTC.
Leadership (MREO)
Mereo Biopharma Group Plc is led by Denise Vera Scots-Knight (age 66), Co-Founder, CEO & Executive Director, per Nexqual as of June 10, 2026 at 06:27 UTC.
| Co-Founder, CEO & Executive Director | Denise Vera Scots-Knight (age 66) |
|---|---|
| Chief Financial Officer | Christine Fox (age 44) |
| Chief Scientific Officer | John A. Lewicki (age 73) |
Major Backers & Investors (MREO)
Notable institutional backers of Mereo Biopharma Group Plc include Rubric Capital Management LP, EcoR1 Capital, LLC, 683 Capital Management LLC, according to Nexqual as of June 10, 2026 at 06:27 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Rubric Capital Management LP | 9.59% |
| EcoR1 Capital, LLC | 8.38% |
| 683 Capital Management LLC | 7.52% |
| Bank of America Corporation | 5.13% |
| Defilade Capital Management, L.P. | 4.74% |
| Newtyn Management, Llc | 4.44% |
| Millennium Management | 2.23% |
| Tejara Capital Ltd | 1.28% |
Source: Nexqual, June 10, 2026 at 06:27 UTC.
From Mereo Biopharma Group Plc's Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States.
- The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
- The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; and licensing agreement with AstraZeneca.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PDSB | PDS Biotechnology Corporation | USD 1.03 | ▲ 0.98% |
| CYPH | Cypherpunk Technologies Inc. | USD 0.68 | ▲ 30.17% |
| ABEO | Abeona Therapeutics Inc. | USD 5.45 | ▼ 0.18% |
| PAVM | PAVmed Inc. | USD 4.68 | ▼ 14.13% |
| CRVS | Corvus Pharmaceuticals, Inc. | USD 11.17 | ▲ 0.45% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 06:27 UTC. This page is informational and not investment advice.